On July 3, Ali Health rose 3.49% in regular trading, trading at HK$3.29/share, with turnover of HK$92.56 million, extending the previous session's gains.

On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo were simultaneously launched exclusively on Ali Health's platform on June 29, reinforcing the company's positioning as a first-launch destination for new specialty drugs. The concentrated selection of Ali Health as the exclusive online first-launch channel by two blockbuster innovative drugs validates the company's channel value and digital service capabilities in the commercialization of innovative pharmaceuticals. Management has previously outlined FY2027 revenue growth guidance of 10% to 15% year-over-year, with the innovative drug category identified as the core growth driver.

Within the Internet and Direct Marketing Retail sector, JD Health rose 5.15%, PA Good Doctor rose 5.09%, JD-SW rose 1.75%, BABA-W rose 0.53%, and Meituan-W rose 0.21%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)